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Abstract
Objectives: To develop and validate a recombinant vaccine to attenuate inflammation in arthritis by sustained
neutralization of the anaphylatoxin C5a.
Methods: We constructed and expressed fusion protein of C5a and maltose binding protein. Efficacy of specific C5a
neutralization was tested using the fusion protein as vaccine in three different arthritis mouse models: collagen induced arthritis
(CIA), chronic relapsing CIA and collagen antibody induced arthritis (CAIA). Levels of anti-C5a antibodies and anti-collagen type II
were measured by ELISA. C5a neutralization assay was done using a rat basophilic leukemia cell-line transfected with the human
C5aR. Complement activity was determined using a hemolytic assay and joint morphology was assessed by histology.
Results: Vaccination of mice with MBP-C5a led to significant reduction of arthritis incidence and severity but not anti-
collagen antibody synthesis. Histology of the MBP-C5a and control (MBP or PBS) vaccinated mice paws confirmed the
vaccination effect. Sera from the vaccinated mice developed C5a-specific neutralizing antibodies, however C5 activation and
formation of the membrane attack complex by C5b were not significantly altered.
Conclusions: Exploitation of host immune response to generate sustained C5a neutralizing antibodies without significantly
compromising C5/C5b activity is a useful strategy for developing an effective vaccine for antibody mediated and C5a
dependent inflammatory diseases. Further developing of such a therapeutic vaccine would be more optimal and cost
effective to attenuate inflammation without affecting host immunity.
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Introduction
Complement is important for host defense but its inappropriate
activation can result in tissue injury and damage. Upon cleavage,
C3 and C5 release C3a and C5a fragments that are potent
anaphylatoxins and leukocyte chemoattractants capable of stim-
ulating and modulating inflammatory responses [1]. Anaphyla-
toxins are implicated in the pathogenesis of several diseases
including allergy, autoimmunity, neurodegenerative diseases and
cancer [2,3] but could also play a protective role against certain
infections [4]. On the other hand, C5b represents the initial
molecule of the terminal complement pathway that play an
essential role in the protection against infectious diseases [5] and in
antigen induced arthritis [6]. Activation of complement results in
the cleavage of C3 leading to C5 activation [7], but C5a can be
generated in the absence of C3 as well [8]. C5a thus generated is
involved in recruitement and activation of inflammatory cells [9],
which can not only regulate adaptive immune responses [10], [11]
but also exhibit anti-inflammatory properties [12]. Since C5 is
essential for immunological functions [5], neutralization of C5a
without affecting the essential function of C5b (formation of MAC)
becomes important [13]. Especially, sustained neutralization of
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13511C5a by exploitation of host immunity will be more optimal and
cost effective for therapeutics.
Development of rheumatoid arthritis (RA) involves a cascade of
inflammatory events leading to joint and cartilage erosions.
Autoantibodies prevalent in RA might play an important role in
the disease development and most widely used animal models are
dependent on antibody-mediated pathologies [14–17]. Antibodies
in the form of immune complexes might play a central role in
triggering inflammatory pathways in the joint [18], especially C5a
binding to these immune complexes can attract granulocytes to the
articular cartilage that can release inflammatory mediators
(proteases, cytokines, chemokines, and reactive oxygen and
nitrogen radicals) perpetuating inflammation and autoimmunity.
In the present study, breaking tolerance towards C5a by
vaccination to induce polyclonal anti-C5a response, C5a/C5b
neutralizing capacity of the induced antibodies and their effect on
arthritis development in various mouse models were assessed.
Results
Effect of C5a vaccination on CIA
Since widely used animal models for RA are dependent on
antibody-mediated pathologies and complement is one of the
major effector mechanisms, we used CIA to test the vaccine
potency of MBP-C5a. Two separate experiments were performed
in male (BALB/c x B10.Q) F1 mice and arthritis was found to be
significantly attenuated (Fig. 1A and B). Importantly, we did not
find any significant difference in CII-specific antibody levels
between groups (Fig. 1C). Histology of the joint sections of CIA
mice vaccinated with PBS (Fig. 2A) or MBP (Fig. 2B) showed
extensive cartilage and bone erosions with massive infiltration of
cells. However, joints from MBP-C5a vaccinated CIA mice were
without any significant cellular infiltration or cartilage and bone
damage (Fig. 2C). Comparable vaccinating effect of MBP-C5a was
observed in mice with another genetic background (B10.Q x
DBA/1) F1 of both sexes and in (BALB/c x B10.Q) F1 female
mice. Similar results were observed when MBP-C5a produced
with a new linker was used in DBA/1 mice (data not shown).
C5a vaccination significantly inhibited arthritis induced
with anti-CII mAbs
To ascertain the therapeutic potential of C5a vaccination at the
effector phase of autoimmune diseases, we used CAIA model using
a cocktail of IgG2b mAbs binding to 3 dominant B cell epitopes of
CII and the C5a vaccinated animals had less frequent and reduced
arthritis severity compared to control vaccinated animals (Fig. 3A
and B). C5a vaccinated, anti-CII antibody injected mice showed
neither significant cellular infiltration nor cartilage and bone
erosions (Fig. 2D), whereas massive infiltration of immunocytes,
pannus formation, fibrin deposition, and distinct bone and
cartilage erosions were observed in the antibody-injected, control
vaccinated mice (Fig. 2E).
Level of C5a- specific antibodies and C5a inhibitory
capacity
All individuals receiving C5a but not control vaccinations
developed anti-C5a IgG antibodies (Fig. 4A and B). Subsequently,
the ability of serum from C5a vaccinated mice to inhibit C5a-
mediated degranulation was determined using a RBL cell line
transfected with human C5aR. The amount of released b-
hexosaminidase was directly proportional to the amount of C5a
added within the range of 2000 ng/ml (240 ng per well) to 2.7 ng/
ml (0.3 ng per well). Serial dilutions of serum were added to 5.6 ng
of C5a and the degree of inhibition was determined. All the
animals receiving C5a but not control vaccination displayed C5a
inhibitory capacity (Fig. 4C). Upon vaccination with MBP-C5a
protein, C5 deficient mice responded with higher anti-C5a levels
than C5 sufficient mice (p=0.018) and anti-C5a antibodies can be
induced in the vaccinated C5 sufficient mice (Fig. 4D).
Inhibition by C5a vaccination of CII-induced relapse of
chronic CIA
To investigate whether MBP-C5a vaccination could be
efficacious in the treatment of chronic arthritis, we immunized
B10.Q (BALB/c 6 B10.Q) F2 mice with rat CII in IFA, which
develops chronic relapsing arthritis [19]. These are genetically
heterogeneous mice, and only mice with severe and active chronic
relapsing arthritis for a minimum period of 120 days but at
arthritis remission at day 210 were selected. For synchronization of
relapse, we reimmunized them with CII emulsified in IFA on day
231. The mice were scored upto day 311 (Fig. 5A). All the mice
developed arthritis in the control group, whereas a significant
decrease in the incidence of arthritis (Fig. 5B) was observed in
MBP-C5a vaccinated group. However, severity of arthritis was
significantly reduced only on two different days (275 and 279),
when all the mice were included for calculations. On the other
hand, when we analyzed significance in severity of arthritis
between the groups using sick mice only, the arthritis severity
tended to be lower in the C5a treated group but reached
significant difference only on day 265 (p=0.0330). High levels of
C5a-specific neutralizing antibodies could be detected in the C5a
but not control vaccinated mice (Fig. 5C).
Vaccination did not affect activation of C5 and activity of
C5b
Since C5b has important functions independent of C5a, we
investigated if vaccination affected the degree of activation of C5
and function of C5b. Sera of mice vaccinated with C5a or control
showed identical hemolytic activity in CIA experiment 2 (Fig. 6A),
CAIA (Fig. 6B) and B10.Q mice (Fig. 6C). Hemolytic assay
measures the whole alternative pathway of complement including
assembly of MAC complex, which includes C5b. Therefore, we
conclude that vaccination against C5a did not affect cleavage of
C5 significantly, i.e. generation of C5b as well as the ability of C5b
to become incorporated into MAC.
Discussion
Targeting complement system is a promising strategy in drug
discovery for treating inflammatory diseases [20–22]. Here, we
developed an immunotherapeutic strategy based on the principle
of introducing an active ingredient that stimulates the production
of antibodies against C5a. The immunotherapeutic fusion protein
(MBP-C5a) developed targets C5a by inducing a polyclonal
antibody response. The pharmacologically active domain (C5a) is
derived from the species to be treated, whereas the fusion protein
is a bacterial protein fused to the N-terminus. Using this strategy,
we produced the fusion proteins using mammalian expression
vectors and evaluated their vaccinating potential. Neutralizing
antibodies induced upon immunization were specific to C5a and
they did not alter C5/C5b activity significantly but led to
attenuation of arthritis in various mouse models. Furthermore,
both C5 deficient and sufficient mice developed anti-C5a response
but the former group responded comparatively stronger, which
demonstrate the presence of tolerance towards C5a and the
possibility of breaking such tolerance by this vaccination
procedure. Importantly, generation of C5a-specific antibodies
did not disturb the normal C5 function.
C5a Vaccine and Arthritis
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the form of immune complexes on or within the joint cartilage can
trigger complement activation and recruitment of FccR+ neutro-
phils leading to release of cytokines, chemokines, destructive
proteases and oxidants [15], [17]. In antibody induced arthritis,
though both the classical and alternative pathway of complement
activation are essential [23], contribution of the alternative pathway
waswellemphasized[24],[25].Furthermore,apoptoticandnecrotic
cells that may be present in affected joints could also activate
complement [26] and so do some cartilage proteins that become
exposed during cartilage damage such as fibromodulin [27].
Activation of complement cascade leads to the formation of C5
convertases, generating C5a and C5b from C5 but complement-
independent enzymes, such as thrombin [28], neutrophil elastase
[29] and a macrophage serine protease [30] can also generate
C5a. Importantly, C5a thus generated is one of the most potent
inflammatory peptides involved in the recruitment and activation
of inflammatory cells, release of granule-based enzymes and
enhancing cell adhesion thereby inducing release of various
inflammatory mediators such as histamine or cytokines all of
which may contribute to innate immune functions or tissue
damage [9], [31], [32]. Furthermore, C5a can act as a general
Figure 1. Inhibition of CIA by MBP-C5a vaccination. Mean clinical score of arthritis severity from two representative experiments; A. (BALB/c x
B10.Q) F1 male mice (8 weeks old) received vaccination subcutaneously of 100 mg MBP-C5a or PBS emulsified in CFA on day 221 and were re-
vaccinated on days 23 and +28 with 50 mg of MBP-C5a or PBS emulsified in IFA as indicated by arrows. B. Similar protocol as above including MBP
group. In both the experiments, mice were immunized with 100 mg of rat CII in CFA on day 0. Serum samples were collected on days 0 and 35. All the
animals were included for calculations and the data represent mean 6 SEM. Significance of differences in severity of arthritis between MBP-C5a and
PBS groups was analyzed by Mann–Whitney U ranking test. *, p,0.05; **, p,0.005 and ***, p,0.001. 100% and 44% of mice developed arthritis in
PBS or MBP-C5a vaccinated groups in the first experiment. During the second experiment, 13%, 60% and 69% of the mice developed arthritis in MBP-
C5a, MBP or PBS vaccinated groups. C) Anti-CII antibody levels in the above two experiments. No significant difference in CII-specific antibody levels
was observed between groups. n, denotes number of mice used in each group.
doi:10.1371/journal.pone.0013511.g001
Figure 2. Histology of joint sections. Effect of C5a inhibition in CIA (A–C) and CAIA (D–E) demonstrated in representative tissue histology. 4–5
mice in each group from the experiments shown in Fig. 1B (CIA) and Fig. 3 (CAIA) were sacrificed and joint morphology was assessed using a
standard haematoxylin/eosin staining protocol. Representative joint sections (6 mm) from QB mice induced with CIA but vaccinated with PBS (A), MBP
(B) or MBP-C5a (C) are shown. Magnification x10. Joint sections from mice induced with CAIA and vaccinated with MBP-C5a (D) or control (PBS) (E) are
shown. Magnification x20.
doi:10.1371/journal.pone.0013511.g002
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involved in the generation of C5a [34]. A single two nucleotide
difference in the FccRIII and IIb gene promoters was found to
determine their inverse responsiveness to C5a [35]. Interestingly,
C5aR antagonist was effective in treating sepsis [36], reducing
antigen-induced arthritis [37] and neurodegeneration [38].
However, blocking of C5aR in small cohort of RA patients
(n=21) did not reduce synovial inflammation [39] and the orally
administered C5aR-antagonist AcF- (OpdChaWR) (PMX53) in
that study binds to C5aR but not C5L2 [40]. Since C5L2 is
uncoupled from G proteins, it has been suggested that this
receptor acts as a decoy receptor that regulates the activity of C5a
and C5a desArg. But a recent study on experimental sepsis
describes a pro-inflammatory role for C5L2, which contributes to
the release of mediators in the inflammatory response [41]. This
becomes especially important because C5L2 is required for the
Figure 3. Effect of MBP-C5a vaccination in CAIA. Four-month-old male QB mice were injected intravenously with a cocktail of three
complement activating monoclonal antibodies (6 mg in total/mouse) binding to CII on day 0, followed by LPS (25 mg/mouse intraperitoneally) on day
+5. MBP-C5a or PBS emulsified in CFA/IFA was injected at the back of the mice on days 221, 210 and 22 as indicated by arrows. The mice were
scored every day and the graphs present (A) incidence (maximal possible value is 100) and (B) severity of arthritis (maximal possible value is 60).
Serum samples were collected from these mice on days 21 and +21 as indicated in the figure. Error bars indicate SEM and n denotes number of mice
in each group. The severity of arthritis was analyzed by Mann–Whitney U ranking test and the incidence by x
2 test. C5a vaccinated animals had less
frequent (38% versus 95%; p,0.0005) as well as severity of arthritis (mean maximum score, p,0.0001) compared to control (PBS with CFA or IFA)
vaccinated animals. n, indicates number of mice in each group.
doi:10.1371/journal.pone.0013511.g003
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has been shown to have an important role in the pathogenesis of
arthritis [42]. Furthermore, since we observed significant reduc-
tion in CAIA induced only with complement fixing antibodies,
another possibility for the inefficiency of C5aR blockade might be
attributed to the presence of non-complement fixing antibody
subclasses in RA patients but this information is not available for
that study [39]. Interestingly, vaccination with C5a could very well
be useful in other clinical conditions since neutralization of C5a
led to amelioration of pathological changes developed in sepsis
[43] and burn-induced cardiac dysfunction [44]. Similarly, genetic
ablation of C5aR is very effective in preventing inflammation in
CAIA [32] and anti-G6PI dependent arthritis [45]. Anti-human
C5aR antibodies prevented arthritis in human C5aR knock-in
mice [46]. Recent studies also showed generation of C5a in vitro by
anti-CII mAb from mouse sera [25].
Importantly, a specific inhibition of C5a biological activity, without
affecting the beneficial effects of C5/C5b, could gain therapeutic
benefit without affecting the protective immune responses [47].
Specific blockade of C5 cleavage thereby preventing C5a generation
was achieved either by a humanized mAb or its single chain [48].
However, studies done with anti-C5 antibodies (Eculizumab) in
arthritis gave mixed results and were published only as web release.
Other way of neutralizing the C5a function is by using pharmaco-
logical inhibitors or antibodies apart from C5a receptor (s) targeting
inhibitors. Here, we could demonstrate the feasibility of generating
anti-C5a antibodies by the host after immunization with C5a fusion
protein that did not compromise C5/C5b activity significantly but led
to attenuation of arthritis in various mouse models. Thus, it is possible
to break tolerance against the self-protein C5a using MBP-C5a
vaccination as evidenced by the high anti-C5a antibody response. The
advantage of this method is to exploit the host immunity for its own
benefit as well as avoiding neutalization of the injected mAb or
inhibitors by the host. An obvious risk with a vaccination approach is
that it could be difficult to reverseinca s eo fsi d ee ff e ct s .A lt ho u g hmo re
work is needed on this direction, we think it is possible to handle; firstly
the increased anti- C5a titers are quite shortlasting and there are
technologies available now for cleaving antibody activities in vivo [49].
Although none of the mice injected with the MBP-C5a vaccine
developed any infectious complications, we can not rule out the
increased riskof intracellular infections because of the neutralization of
C5a [10]. Thus, complement inhibition as a therapeutic treatment
could be achieved by interventions aimed at blocking the pathological
activities of complement activation products, while avoiding disrup-
tion of the role of complement in host immunity. Thus, this approach
is more specific than depleting C5 and since the production of
antibodies occur at the site of inflammation it could be a treatment
that has limited risk of side effects. However, obviously more studies
are needed before using this strategy for clinical trials.
Materials and Methods
Ethics statement
All experiments were performed on age-matched mice between
the ages of 8 and 16 weeks with the approval of animal ethics
committee, Malmo ¨-Lund region, Sweden.
Figure 4. Determination of C5a-specific antibody levels and C5a neutralization. Anti-C5a antibody levels (A) in the sera collected from
mice on day 35 immunized for CIA. As described in Fig. 1B, (BALB/c x B10.Q) F1 male mice (8 weeks old) received vaccination subcutaneously of
100 mg MBP-C5a or PBS emulsified in CFA at day 221 and were re-vaccinated on days 23 and +28 with 50 mg of MBP-C5a or PBS emulsified in IFA. All
the mice were immunized with 100 mg of rat CII in CFA on day 0. Anti-C5a antibody levels (B) and C5a neutralization capacity (C) present in the sera
collected from mice on day 21 and day 21. The mice were vaccinated with MBP-C5a or PBS emulsified in CFA/IFA on days 221, 210 and 22 and
used in CAIA experiment on day 0, as shown in Fig. 3. Anti-C5a antibody levels (D) present on day 35 in B10.Q mice and the C5 deficient congenic
mice strain B10.Q.NOD-Cia2 (NB2). Groups of 8 weeks old mice received vaccination subcutaneously of 100 mg MBP-C5a or PBS emulsified in CFA on
day 221 and were re-vaccinated on days 23 and +28 with 50 mg of MBP-C5a or PBS emulsified in IFA. Upon vaccination with MBP-C5a protein, C5
deficient mice (NB2) responded with higher anti-C5a levels than C5 sufficient B10.Q mice (p=0.018). n, indicates number of mice in each group. All
the assays were done in triplicates.
doi:10.1371/journal.pone.0013511.g004
C5a Vaccine and Arthritis
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13511Mice
Breeding pairs of BALB/cJ and B10.Q mice were from Jackson
Laboratories (Bar Harbor, ME) and Prof. Jan Klein (Professor
Emeritus, Tu ¨bingen University, Tu ¨bingen, Germany) respective-
ly. The congenic B10.Q.NOD-Cia2 mice used were C5 deficient
[50].
Construction, expression and purification of recombinant
MBP-C5a
Mouse liver Poly A+ RNA (Clontech Laboratories Inc., CA) was
used for amplifying cDNA encoding C5a by One-Step RT-PCR
(Qiagen Inc., CA) using forward primer Va59 (CGCCAGCTGC-
TAAGGCAGAAAATAGAAG) and reverse primer Va39 (CGC-
Figure 5. Effect of MBP-C5a vaccination on chronic arthritis. Frequency (A), mean arthritis score (B) and levels of C5a-specific antibodies
(C) were compared between MBP-C5a and PBS vaccinated groups. B10.Q (BALB/c x B10.Q)F2 mice of both gender (8 weeks old) were immunized
with 100 mg of rat CII emulsified in IFA on day 0 at the base of the tail and boosted on day 35 with 50 mgo fr a tC I Ii nI F Aa si n d i c a t e db ya r r o w s .
The mice were scored for a period of 210 days for arthritis development. Mice that developed chronic arthritis and at arthritis remission were
selected for the treatment experiment. All selected animals received vaccination subcutaneously of 100 mg of MBP-C5a or PBS emulsified in CFA
on day 210 and were re-vaccinated on days 228 and 252 with 50 mg of MBP-C5a or PBS emulsified in IFA s.c. at the back. All the animals were re-
immunized for synchronization of arthritis induction on day 231 with 50 mgo fr a tC I Ii nI F Aa n ds c o r e dt h en e x t8 0d a y sf o rc l i n i c a ls i g n so f
arthritis up to day 311 (from first day of CII immunization). Serum samples were collected on day 231 and 292. Statistical analysis for mean
arthritis score was done on all days (d259 to d311) but the significance between groups was found only on days 275 and 279. All data represent
mean 6 SEM. *, p,0.05 and **, p,0.005. n, indicates number of mice in each group. All t h em i c ew e r ei n c l u d e df o rcalculation of arthritis
susceptibility and severity.
doi:10.1371/journal.pone.0013511.g005
C5a Vaccine and Arthritis
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and Fig. 4D (C5 sufficient B10.Q and C5 deficient NB2 mice). Serum samples were analyzed for C5 activity A) on days 221 and 35 from MBP-C5a, MBP
or PBS vaccinated mice used in CIA experiment, B) day 0 and 35 from MBP-C5a or PBS vaccinated mice used in CAIA experiment and C) day 221, 34
and 90 from MBP-C5a or PBS vaccinated C5 sufficient B10.Q or C5 deficient NB2 congenic mice. Great care was taken in order to preserve
complement activity. Activity of the alternative pathway of complement was measured in hemolytic assay in which rabbit erythrocytes were
incubated with mouse sera and the amount of hemoglobin released in supernatants due to lysis was determined spectrophotometrically. All the
assays were done in triplicates. There was no significant difference in complement activity between MBP-C5a and MBP control (A) but there was a
significant difference in complement activity when MBP-C5a and PBS groups were compared (in Fig. A and B but not in C) using t-test (paired). Error
bars indicate 6 SD.
doi:10.1371/journal.pone.0013511.g006
C5a Vaccine and Arthritis
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plified using forward primer 816 (CCAGAATTCCACCATCAC-
CATCACCATCTCGAGCCGCGGGCCGATATGAAAATCGA-
AGAAGG) and reverse primer Va39. Plasmid DNA was prepared
using Qiagen Midiprep kit and EBNA-293 cells were transfected using
lipofectamine 2000 (Invitrogen AB, Sweden). Cells were expanded and
supernatants were collected for purification using ion exchange (SP
Sepharose FF) and affinity (amylose) chromatography. SDS-PAGE,
size exclusion chromatography and western blot were used to
determine the purity of the proteins (data not shown).
Detection of anti-C5a antibodies in mouse serum
Serum IgG anti-C5a antibodies were determined by a semi-
quantitative ELISA. Briefly, samples were titrated in five-fold
dilutions similar to reference serum in ELISA plates coated with
C5a (4 mg/ml). Alkaline phosphatase-conjugated goat anti-mouse
IgG Fcc-specific antibody (Jackson ImmunoResearch, PA) and p-
nitrophenyl phosphatase and buffer tablets (Sigma-Aldrich, MO)
were used as detection system. The absorbance was read at
405 nm. The titer (the dilution yielding a 50% reduction of
absorbance) was determined for each sample and the reference
serum. The titer of each sample was related to the reference serum
and this was termed as relative titer (%).
C5a neutralization assay
A rat basophilic leukemia (RBL) cell-line transfected with
human C5aR was used. Upon binding of C5a to the receptor, N-
acetyl-b-D-glucosaminidase (NAG) is released, which is quantified
by addition of its substrate. Serum containing antibodies that
inhibits this binding will result in a decreased absorbance. At first,
RBL cells (2610
6 cells/ml) were incubated 3 minutes in 37uC with
cytochalasin B (Sigma-Aldrich) to enhance C5a-induced enzyme
release. Serum samples were incubated in HBSS medium
containing 2 mM HEPES, 0.2% BSA and 40 mg/ml DL-2-
mecaptmethyl-3-guanidinoethylthiopropanoic acid (Calbiochem)
for one hour at 37uC, followed by addition of mouse C5a (HyCult
Biotechnology) at 35 ng/ml and incubation. As an internal
control, C5a was incubated with HBSS medium. Triton X-100
(0.2%) was added as a control for maximal enzyme release. Plain
medium and a reference serum were used as negative and positive
controls respectively. Eighty ml of the RBL cell suspension was
thereafter exposed to the serum containing C5a for 6 min at 37uC.
To stop the reaction, the plates were centrifuged for 3 min, 10006
g, at 4uC. Seventy ml of the supernatant was transferred to a 96
well plate with 70 ml of substrate solution [7.5 mM of p-
nitrophenyl N-acetyl-b-D-glucosaminide (Sigma-Aldrich) dissolved
in 42.5 mM sodium acetate buffer, pH 4.5] and incubated at
37uC for 3 hours. After incubation, 70 ml of glycine buffer (0.2 M,
pH 10.7) was added and the absorbance was read at 405 nm.
Induction and vaccination of collagen induced arthritis –
classical and chronic relapse
(BALB/c x B10.Q mice) F1 mice were vaccinated with 100 mg
of MBP-C5a, MBP or PBS emulsified in CFA, s.c. on day -21 and
re-vaccinated on days -3 and +28 with 50 mg of MBP-C5a, MBP
or PBS emulsified in IFA s.c. For induction of arthritis, mice were
immunized with 100 mg of rat CII (rCII), emulsified 1:1 in CFA
(Difco, Detroit, MI) on day 0. Mice were monitored for arthritis on
the indicated days and serum samples were collected on days 0
and 35.
For induction of chronic relapsing arthritis, B10.Q (BALB/c x
B10.Q)F2 mice were immunized with 100 mg of rCII emulsified in
IFA on day 0 and boosted on day 35 with 50 mg of rCII in IFA.
Mice that developed chronic arthritis (defined as severe arthritis
for a minimum of 120 days) but exhibited no active arthritis at day
210 were selected for treatment. All selected animals received
vaccination of 100 mg of MBP-C5a or PBS emulsified in CFA, s.c.
on day 210 and re-vaccination on days 228 and 252 with 50 mgo f
MBP-C5a or PBS emulsified in IFA s.c. All the animals were
reimmunized for synchronization of arthritis on day 231 with
50 mg of rCII in IFA and scored upto day 311 (from first day of
CII immunization). Serum samples were collected on days 231
and 292.
Induction and vaccination of collagen antibody induced
arthritis (CAIA)
B cell hybridomas specific to CII were generated and
characterized previously [51,52]. Antibodies from clone M2139
(IgG2b) bind J1 epitopes of CII (551–564; GERGAAGIAGPK),
CIIC2 (IgG2b) bind D3 epitopes of CII (687–698; RGAQGPP-
GATGF), and UL1 (IgG2b) bind U1 epitopes of CII (494–504;
GLVGPRGERGF). Groups of mice were vaccinated with 100 mg
of MBP-C5a or PBS emulsified in CFA, s.c. on day 221 and
revaccinated on days 210 and 22 with 50 mg of MBP-C5a or
PBS emulsified in IFA s.c. A cocktail of the 3 mAbs (6 mg per
mouse) was injected i.v. and on day 5, LPS (25 mg/mice) was
injected i.p. to enhance incidence and severity of arthritis.
Clinical evaluation of arthritis and histology
Scoring of animals was done blindly using a scoring system
based on the number of inflamed joints in each paw, inflammation
being defined by swelling and redness [53]. In this scoring system
each inflamed toe or knuckle gives one point, whereas an inflamed
wrist or ankle gives five points, resulting in a score of 0–15 (5
toes+5 knuckles+1 wrist/ankle) for each paw and 0–60 points for
each mouse. Paws from each group of mice (4–5 per group) were
dissected, fixed, decalcified, dehydrated, and embedded in
paraffin. Sections (6 mm) were stained with hematoxylin-eosin.
Anti-CII antibody response
The amounts of total anti-CII IgG were determined using
quantitative ELISA [54]. Sera from non-immunized syngenic
mice were used as a negative control and did not contain any
detectable amounts of anti-CII Abs. Affinity purified anti-CII
antibody from pooled sera of CII immunized mice was used as
standard.
Complement analysis
Complement activity was determined using a hemolytic assay.
Rabbit erythrocytes were washed in Mg-EGTA buffer (2.5 mM
veronal buffer pH 7.3, 70 mM NaCl, 140 mM glucose, 0.1%
gelatin, 7 mM MgCl2 and 10 mM EGTA) and resuspended at
0.5610
9 cells/ml. Mouse serum (5 ml) was incubated for 3 h at
37uC with 20 ml of erythrocyte suspension in 100 ml of Mg-EGTA
buffer and the degree of lysis was determined by the amount of
released hemoglobin measured at 405 nm and the absorbance
provided by serum itself was subtracted from the values. Low level
of C5 activity in C5 deficient mice (Fig. 6C) also served as the
negative control for C5 assays.
Statistical analyses
All the mice were included for calculation of arthritis
susceptibility and severity. Severity and incidence of arthritis was
analyzed by Mann Whitney U test and Chi Square analysis
respectively using Statview 5.0.1 (SAS Institute, NC). Significance
was considered when p,0.05.
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